Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Oct;10(10):1442-1444.
doi: 10.1158/2159-8290.CD-20-1087.

Immunosurveillance and Regression in the Context of Squamous Pulmonary Premalignancy

Affiliations
Comment

Immunosurveillance and Regression in the Context of Squamous Pulmonary Premalignancy

Kostyantyn Krysan et al. Cancer Discov. 2020 Oct.

Abstract

In this issue of Cancer Discovery, Pennycuick and colleagues comprehensively evaluate the immune contexture of progressive and regressive lesions in squamous pulmonary premalignancy. The authors dissect the molecular features of these lesions and the potential pathways of immune escape operative in progression to invasive cancer.See related article by Pennycuick et al., p. 1489.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest

Steven M. Dubinett is an advisory board member for EarlyDx Inc., T-Cure Bioscience Inc., LungLife AI, and the Johnson and Johnson Lung Cancer Initiative

Figures

Figure 1:
Figure 1:
Progression of squamous premalignancy may be associated with suppression of immune surveillance through: (A) impairment of antigen processing and presentation capacity, (B) impairment of IFN-g signaling, (C) increased expression of immune check-points (iCPs), and (D) the release of cytokines inhibiting T cell activation while promoting recruitment of myeloid-derived suppressor cells (MDSCs).

Comment on

  • Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer.
    Pennycuick A, Teixeira VH, AbdulJabbar K, Raza SEA, Lund T, Akarca AU, Rosenthal R, Kalinke L, Chandrasekharan DP, Pipinikas CP, Lee-Six H, Hynds RE, Gowers KHC, Henry JY, Millar FR, Hagos YB, Denais C, Falzon M, Moore DA, Antoniou S, Durrenberger PF, Furness AJ, Carroll B, Marceaux C, Asselin-Labat ML, Larson W, Betts C, Coussens LM, Thakrar RM, George J, Swanton C, Thirlwell C, Campbell PJ, Marafioti T, Yuan Y, Quezada SA, McGranahan N, Janes SM. Pennycuick A, et al. Cancer Discov. 2020 Oct;10(10):1489-1499. doi: 10.1158/2159-8290.CD-19-1366. Epub 2020 Jul 20. Cancer Discov. 2020. PMID: 32690541 Free PMC article.

References

    1. Pennycuick A, Teixeira VH, AbdulJabbar K, Raza SEA, Lund T, Akarca AU, et al.Immune surveillance in clinical regression of pre-invasive squamous cell lung cancer. Cancer Discov 2020; - PMC - PubMed
    1. Wistuba II, Berry J, Behrens C, Maitra A, Shivapurkar N, Milchgrub S, et al.Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res 2000;6:2604–10. - PMC - PubMed
    1. Merrick DT, Edwards MG, Franklin WA, Sugita M, Keith RL, Miller YE, et al.Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Res 2018;78:4971–83. - PMC - PubMed
    1. Krysan K, Tran LM, Grimes BS, Fishbein GA, Seki A, Gardner BK, et al.The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy. Cancer Res 2019;79:5022–33. - PMC - PubMed
    1. Teixeira VH, Pipinikas CP, Pennycuick A, Lee-Six H, Chandrasekharan D, Beane J, et al.Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions. Nat Med 2019;25:517–25. - PMC - PubMed

Publication types